Skip to main content
Premium Trial:

Request an Annual Quote

BioCrystal, Surface Logix Recently Awarded US Patents for Assay Tech

Premium

BioCrystal has been awarded US Patent No. 6,811,752, “Device having microchambers and microfluidics.” Emilio Barbera-Guillem is the inventor listed on the patent.

According to its abstract, the patent protects a device comprising a plurality of microchambers having a closed vented environment, wherein each microchamber is in operative communication with a filling port and a vent aperture. The device further comprises a base sandwiched between two liquid-impermeable membranes, with at least one of the membranes being gas permeable, the abstract states. Also provided is a method for introducing fluid into a plurality of microchambers of the device, wherein each filling port is aligned with a pipette tip, and the fluid is introduced into and through the filling port. The fluid then flows along a fluid flow groove providing fluid flow communication between the filling port and the microchamber, and into the microchamber, the abstract states.


Surface Logix has been awarded US Patent No. 6,811,968, “Method of monitoring cell motility and chemotaxis.” Multiple inventors are listed on the patent, led by Gregory Kirk.

According to its abstract, the patent discloses a method of monitoring chemotaxis or chemoinvasion using a device that includes: a support member, and a top member mounted to the support member by being placed in substantially fluid-tight, conformal contact with the support member. The support member and top member are configured such that they together define a discrete assay chamber, which includes a first-well region … configured to receive a soluble test substance therein; a second-well region … configured to receive a sample comprising cells therein; and a channel region including at least one channel connecting the first-well region and the second-well region. The method further comprises placing the soluble test substance in the first well; forming a solution concentration gradient along a longitudinal axis of the chamber; placing a first sample comprising cells in the second well; and monitoring chemotaxis of the cells, the abstract states.


Michael Corey has been awarded US Patent No. 6,811,990, “Methods and compositions for coupled luminescent assays.” Inventors listed on the patent are Michael Corey and Robert Kinders.

According to its abstract, the patent provides a set of methods and compositions for homogeneous coupled luminescent assays for cytotoxicity and/or proliferation of cells, as well as for enzymatic activity. In both cases the activities of the enzymes of interest are coupled to production of a high-energy molecule, which serves as a substrate for the production of light by a luciferase, typically in a single reagent mixture, the abstract states. The patent also describes a three-minute, one-step phosphatase assay. The ability to couple the activity of interest to light production in a one-step procedure gives rise to extremely rapid and flexible methods for measurement of cytotoxic effects and enzymatic activities, and the assay methods are highly suitable for use in high-throughput screening procedures, the abstract states.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.